IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

Iovance Biotherapeutics reported a wider-than-expected Q2 2025 loss and missed revenue consensus, with total sales of $60.0 million despite strong Amtagvi sales of $54.1 million offsetting a significant 68% decline in Proleukin revenue. The company announced a strategic restructuring plan to save over $100 million annually starting in 2025, including a 19% workforce reduction, which is expected to extend its cash runway into Q4 2026. However, shares plummeted nearly 29% in after-market trading following the disclosure that Iovance voluntarily withdrew Amtagvi's regulatory filing in the European Union due to a lack of alignment with the EMA on clinical data, delaying a key market expansion despite reiterated full-year revenue guidance and ongoing pipeline advancements.

Analysis

Iovance Biotherapeutics' second-quarter 2025 results present a deeply mixed operational picture, overshadowed by a significant regulatory setback. While total revenue grew 93% year-over-year to $60.0 million, it missed consensus estimates of $66.4 million, and the company reported a wider-than-expected loss of 33 cents per share. The revenue composition reveals a stark divergence: the new TIL therapy, Amtagvi, generated strong sales of $54.1 million, exceeding estimates and reflecting robust initial demand with over 100 patients infused. Conversely, sales of the older IL-2 product, Proleukin, collapsed 68% year-over-year to just $5.9 million, drastically missing the $18 million estimate. In response to rising R&D expenses, which grew 28% to $79.4 million, the company initiated a substantial restructuring plan to save over $100 million annually, involving a 19% workforce reduction. This move is designed to extend the cash runway into the fourth quarter of 2026. However, the most impactful development was the voluntary withdrawal of Amtagvi's regulatory application in the European Union due to a lack of alignment with the EMA, which triggered a nearly 29% collapse in the share price and pushes the stock's year-to-date decline to 64%. This development materially delays a key growth vector, placing immense pressure on the US Amtagvi launch and future pipeline data.

Key Decisions for Investors

• Given the voluntary withdrawal of Amtagvi's EU application, investors should re-evaluate valuation models to account for the significant delay and uncertainty in European market entry, which was the primary catalyst for the stock's 29% after-market decline.
• The strong initial US demand for Amtagvi, which drove sales of $54.1 million this quarter, is now the critical value driver, making its sales ramp-up towards the reiterated $250-$300 million full-year guidance the key metric to monitor.
• Pay close attention to upcoming pipeline catalysts, particularly the phase II data for Amtagvi in non-small cell lung cancer expected by year-end, as positive results could provide a much-needed positive catalyst and path to label expansion.
• Scrutinize the execution of the cost-saving plan and the projected net cash burn of less than $245 million over the next year, as the extended cash runway to Q4 2026 is vital for funding operations until key clinical and regulatory milestones are achieved.